Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient.
Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.
“Starpharma's dendrimer technology can make a real and important contribution to the fight against a range of diseases. Through our robust partnerships with global industry leaders, we are uniquely positioned to address these challenges."
Mr Robert Thomas AO
Starpharma Chairman
Dendrimers are precisely manufactured nanoparticles with unique properties, such as size, structure, branching, polyvalency, and water solubility, making them advantageous in medical and pharmaceutical applications.
Starpharma has developed the DEP® (dendrimer enhanced product) drug delivery platform to enhance the delivery and effectiveness of pharmaceutical drugs. This technology has the potential to offer significant therapeutic and commercial opportunities for a wide range of drugs across various therapeutic areas.
Starpharma has developed a pipeline of novel DEP® oncology products. Its clinical-stage assets, DEP® SN38, DEP® cabazitaxel, and DEP® docetaxel, have demonstrated promising efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP® radiopharmaceuticals and DEP® Antibody-Drug Conjugates (ADCs) in development.
Commercial partnerships are key to Starpharma's business and offer significant optionality. Our partnerships involve leveraging our proprietary dendrimer technology platform to develop and commercialise innovative products to meet significant clinical needs and create value for all stakeholders.
Starpharma has developed and commercialised three products based on its innovative proprietary dendrimer called SPL7013 (astodrimer sodium), which has antiviral and antimicrobial properties through a physical mechanism of action. These products are marketed in regions where marketing authorisation has been achieved.
Starpharma is listed on the Australian Securities Exchange (ASX: SPL) and the US OTCQX (OTCQX: SPHRY). Our Investor Centre contains Starpharma's financial reports and presentations, corporate governance policy, and other information for investors.
This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.
You have selected a link that will redirect you to a site maintained by a third party who is solely responsible for its contents.
Starpharma provides this link as a service to website visitors. Starpharma is not responsible for the privacy policy of any third party websites. Read the privacy policy of every website you visit.
To proceed, click ‘continue’.
